Prescient Therapeutics hails collaboration with MD Anderson Cancer Center for blood cancer therapy
Prescient Therapeutics Ltd (ASX:PTX) CEO and managing director Steven Yatomi-Clarke chats with Andrew Scott from Proactive about the...
Prescient Therapeutics Ltd (ASX:PTX) CEO and managing director Steven Yatomi-Clarke chats with Andrew Scott from Proactive about the...
Prescient will join with the US’s largest cancer centre with the goal of creating best-in-class,...
Prescient Therapeutics (ASX: PTX) takes a crucial step in advancing its next-generation cell therapy platform, OmniCAR. The...
Prescient Therapeutics (PTX) has partnered with the largest cancer centre in the US to create best-in-class,...
Prescient Therapeutics (ASX: PTX) has entered a strategic collaboration with the largest cancer centre in US...
"We believe that OmniCAR is a transformational platform for cellular immunotherapy, and we look forward...
Prescient’s work is being considered a game-changer in advancing CAR-T therapies for cancer treatment and...
Prescient Therapeutics Ltd (ASX:PTX) managing director and CEO Steven Yatomi-Clarke speaks with Proactive’s Elisha Newell about...
Clinical-stage oncology firm Prescient Therapeutics (ASX: PTX) announces a Share Purchase Plan (SPP) to raise AU$8.0 million.
Clinical stage oncology company Prescient Therapeutics to progress its deep pipeline of innovative cancer therapies...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.